All the proposed resolutions in the notice were approved by the Extraordinary General Meeting. The Extraordinary General Meeting approved among other things the private placement of MNOK 45.2.
Statement from the Company's auditor regarding conversion of debt is attached (in Norwegian only).
A prospectus in regards to the listing of the shares issued under the private placement will be published as soon as it is approved by the Norwegian FSA.
For further information, please contact:
Jon Olav Ødegård, CEO Hofseth BioCare ASA
Tel: +47 936 32 966
E-mail: joo@h-bc.no
About Hofseth BioCare:
Hofseth BioCare is a Norwegian biomarine company with the key objective to provide high value added biomarine ingredients for human applications. The Company is founded on the core value of sustainability and optimal use of natural resources. Through innovative production technology and logistics, Hofseth BioCare is able to preserve the quality of protein, calcium and oil extracted from fish off-cuts. Products that previously could only be used as animal feed can now be made suitable for human consumption. HBCs objective is thus to contribute to efficient use of marine resources and entering the higher profit market of quality ingredients for human applications.
This information is subject of the disclosure requirements acc. to vphl § 5-12 (Norwegian Securities Trading Act).
